Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2004-02-25 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Commences ShockRounds Due Diligence/Appointment of Director 2 pages ?Kb
Regulatory Filings
2004-02-25 English
Placement - Notice pursuant to ASIC Class Order 2 pages ?Kb
Regulatory Filings
2004-02-24 English
Half Yearly Report & Half Year Accounts 17 pages ?Kb
Regulatory Filings
2004-02-24 English
Acq of exclusive rights to commercialise Shockrounds 11 pages ?Kb
Regulatory Filings
2004-02-23 English
Appendix 3B - Balance of shares approved at AGM 9 pages ?Kb
Regulatory Filings
2004-02-22 English
Change of Company Secretary 2 pages ?Kb
Regulatory Filings
2004-02-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.